MP33-08 PROGESTERONE SURGE DECREASES THE SEVERITY OF URETERAL STENT RELATED SYMPTOMS IN FEMALE PATIENTS

Abstract

You have accessJournal of UrologyStone Disease: Basic Research I1 Apr 2015MP33-08 PROGESTERONE SURGE DECREASES THE SEVERITY OF URETERAL STENT RELATED SYMPTOMS IN FEMALE PATIENTS Emrah Yuruk, Aykut Colakerol, and Ege Can Serefoglu Emrah YurukEmrah Yuruk More articles by this author , Aykut ColakerolAykut Colakerol More articles by this author , and Ege Can SerefogluEge Can Serefoglu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.569AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Ureteral stents are widely used after ureteral manipulation. However, most of the patients report some degree of discomfort related to these stents. It is well known that progesterone causes relaxation of the smooth muscles of the urinary tract, including the ureters. The aim of this study is to evaluate whether the progesterone surge seen during the luteal phase of the menstrual cycle decreases the severity of stent related symptoms. METHODS Between May 2014 - October 2015, female patients aged 18 to 40 years, who required ureteral stent placement, were included to the study. Patients who were pregnant, using oral contraceptives or experiencing irregular menstrual cycles were excluded. Patients using anticholinergic or alpha-receptor blocking drugs were also excluded, along with the ones who required daily analgesic administration. All patients recorded the date of their last menstruation and they are instructed to complete the visual analogue scale (VAS, 0-10) scores twice per day postoperatively for a period of one month. RESULTS A total of 32 patients with a mean age of 29.28±5.98 (range: 18-41) recorded daily VAS scores. After exclusion of 3 patients because of frequent analgesic use, 29 patients were included. Ureteral stents were used after flexible ureteroscopy, percutaneous nephrolithotomy, ureteroscopy, ureteral stricture, shock-wave lithotripsy and gynecologic pathologies in 9 (31%), 1 (3.4%), 11 (37.9%), 1 (3.4%), 5 (17.2%) and 2 (6.8%) patients, respectively. The VAS scores were significantly lower on 24th (p=0.011, r=0.586), 25th (p=0.043, r=0.482), 26th (p=0.001, r=0.722) and 27th (p=0.0001, r=0.801) days of menstruation. The association of serum progesterone levels with daily VAS score changes is shown on Figure-1. CONCLUSIONS Progesterone surge seen during the luteal phase of the menstrual cycle seems to decrease stent related symptoms in female patients. Further clinical studies are required to evaluate whether progesterone containing therapies can be used for relieving the bother in patients with ureteral stents. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e376 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Emrah Yuruk More articles by this author Aykut Colakerol More articles by this author Ege Can Serefoglu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...